Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 6, 2002, Pages 1012-1017

  Herrington, David M ^a   Vittinghoff, Eric ^a   Howard, Timothy D ^a   Major, David A ^a   Owen, John ^a   Reboussin, David M ^a   Bowden, Donald ^a   Bittner, Vera ^a   Simon, Joel A ^a   Grady, Deborah ^a   Hulley, Stephen B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiology; Genetics; Risk factors for stroke; Thrombosis risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOEMBOLISM;

AGED; CASE-CONTROL STUDIES; CORONARY DISEASE; FACTOR V; FEMALE; GENETIC SCREENING; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MULTICENTER STUDIES; MUTATION; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; RISK; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0036072092     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000018301.91721.94     Document Type: Article

References (45)

1. Mutation in blood coagulation factor V associated with resistance to activated protein C
2. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
3. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
4. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
5. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
6. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
7. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden
8. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy
9. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy
10. Risk factors associated with postpartum ovarian vein thrombosis
11. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden
12. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
13. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen
14. DVT following oral contraceptive therapy in association with homozygous factor V Leiden
15. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden
16. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: Relationships to hormone replacement therapy
17. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: Results of the randomized, double-blind, placebo-controlled Estrogen in Venous Thromboembolism Trial (EVTET)
18. Risk of venous thrombosis with hormone-replacement therapy
19. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study
20. Heart and Estrogen/Progestin Replacement Study (HERS): Design, methods, and baseline characteristics
21. The Estrogen Replacement and Atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort
22. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
23. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
24. Unbalanced repeated-measures models with structured covariance matrices
25. Confidence interval estimation of interaction
26. Cardiovascular implications of the factor V Leiden mutation
27. Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective
28. Resistance to activated protein C in healthy women taking oral contraceptives
29. Lowered activated protein C-sensitivity ratio related to increased factor VIII-clotting activity
30. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives
31. Development of resistance to activated protein C during pregnancy
32. Resistance to activated protein C is reduced in women using oral contraceptives
33. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: Prospective cohort study and review of the literature
34. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients: The French Network on the behalf of INSERM
35. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families?
36. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation
37. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment
38. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?
39. A clinical trial of estrogen-replacement therapy after ischemic stroke
40. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial
41. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy
42. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: A prospective, observational study
43. Task Force 6: Cost effectiveness of assessment and management of risk factors